SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
Cell Res
.
2022 Mar;32(3):322-324.
doi: 10.1038/s41422-022-00618-w.
Epub 2022 Jan 20.
Authors
Pengfei Li
1
,
Yining Wang
1
,
Marla Lavrijsen
1
,
Mart M Lamers
2
,
Annemarie C de Vries
1
,
Robbert J Rottier
3
4
,
Marco J Bruno
1
,
Maikel P Peppelenbosch
1
,
Bart L Haagmans
2
,
Qiuwei Pan
5
Affiliations
1
Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.
2
Viroscience Department, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.
3
Department of Pediatric Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
4
Department of Cell Biology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.
5
Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands. q.pan@erasmusmc.nl.
PMID:
35058606
PMCID:
PMC8771185
DOI:
10.1038/s41422-022-00618-w
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
COVID-19*
Cytidine / analogs & derivatives
Humans
Hydroxylamines
SARS-CoV-2*
Substances
Hydroxylamines
Cytidine
molnupiravir
Supplementary concepts
SARS-CoV-2 variants